In Vitro Activity of a Novel Siderophore-Cephalosporin LCB10-0200 (GT-1), and LCB10-0200/Avibactam, against Carbapenem-Resistant Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa Strains at a Tertiary Hospital in Korea

Autor:	Hyun-Sook Lee, Roshan D'Souza, Kevin Nguyen, Chul Soon Park, Hyun Soo Seo, Le Phuong Nguyen, Thao Nguyen Vu, Richard C. White, Dongeun Yong, Eris Jang, Young Lag Cho, Derrick E. Fouts, An H.T. Pham, Hung Mai, Naina Adren Pinto, Karrie Goglin
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	0301 basic medicine Klebsiella pneumoniae Avibactam 030106 microbiology carbapenem resistance Pharmaceutical Science Ceftazidime Aztreonam medicine.disease_cause Meropenem Article Microbiology 03 medical and health sciences chemistry.chemical_compound Pharmacy and materia medica LCB10-0200/Avibactam Drug Discovery medicine polycyclic compounds Escherichia coli biology Pseudomonas aeruginosa siderophore-antibiotic conjugate biochemical phenomena metabolism and nutrition biology.organism_classification bacterial infections and mycoses Acinetobacter baumannii RS1-441 030104 developmental biology chemistry Medicine Molecular Medicine bacteria LCB10-0200 (GT-1) medicine.drug
Zdroj:	Pharmaceuticals Volume 14 Issue 4 Pharmaceuticals, Vol 14, Iss 370, p 370 (2021)
ISSN:	1424-8247
Popis:	The siderophore–antibiotic conjugate LCB10-0200 (a.k.a. GT-1) has been developed to combat multidrug-resistant Gram-negative bacteria. In this study, the in vitro activity of LCB10-0200 and LCB10-0200/avibactam (AVI) has been investigated against carbapenem-resistant Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Minimal inhibitory concentrations (MICs) of LCB10-0200, LCB10-0200/AVI, aztreonam, aztreonam/AVI, ceftazidime, ceftazidime/AVI, and meropenem were measured using the agar dilution method. Whole genome sequencing was performed using Illumina and the resistome was analyzed. LCB10-0200 displayed stronger activity than the comparator drugs in meropenem-resistant E. coli and K. pneumoniae, and the addition of AVI enhanced the LCB10-0200 activity to MIC ≤ 0.12 mg/L for 90.5% of isolates. In contrast, whereas LCB10-0200 alone showed potent activity against meropenem-resistant A. baumannii and P. aeruginosa at MIC ≤ 4 mg/L for 84.3% of isolates, the combination with AVI did not improve its activity. LCB10-0200/AVI was active against CTX-M-, SHV-, CMY-, and KPC- producing E. coli and K. pneumoniae, while LCB10-0200 alone was active against ADC-, OXA-, and VIM- producing A. baumannii and P. aeruginosa. Both LCB10-0200 and LCB10-0200/AVI displayed low activity against IMP- and NDM- producing strains. LCB10-0200 alone exhibited strong activity against selected strains. The addition of AVI significantly increased LCB10-0200 activity against carbapenem-resistant E. coli, K. pneumoniae.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a598f6880b601c54fe3bbe1728e4be5a http://europepmc.org/articles/PMC8072773 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.